The neutrophil to lymphocyte ratio predicts the response to neoadjuvant chemotherapy in luminal B breast cancer

Simple item page
dc.catalogadorpva
dc.contributor.authorMauricio Rivas
dc.contributor.authorFrancisco Acevedo
dc.contributor.authorFrancisco Dominguez
dc.contributor.authorHector Galindo
dc.contributor.authorMauricio Camus
dc.contributor.authorDavid Oddo
dc.contributor.authorAlejandra Villarroel
dc.contributor.authorDravna Razmilic
dc.contributor.authorJose Peña
dc.contributor.authorMatias Munoz Medel
dc.contributor.authorMaria Elena Navarro
dc.contributor.authorAlejandra Perez-Sepulveda
dc.contributor.authorLidia Medina
dc.contributor.authorTomas Merino
dc.contributor.authorJuan Briones
dc.contributor.authorAlexis Kalergis
dc.contributor.authorCesar Sanchez
dc.date.accessioned2024-01-19T18:21:50Z
dc.date.available2024-01-19T18:21:50Z
dc.date.issued2019
dc.description.abstractObjective: Tumor response to neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients is a predictor for overall survival. The aim of our study was to determine a relationship between the neutrophil to lymphocyte ratio (NLR) prior to NAC, BC subtypes and the probability of a pathologic complete response (pCR). Materials and Methods: Medical records were collected retrospectively from Centro de Cancer at Red Salud UC-Christus. Clinical data collected included peripheral blood cell counts, BC subtype at diagnosis and the pathology report of surgery after chemotherapy. Results: A total of 88 patients were analyzed. Approximately, a 25% had a pCR, and displayed a significant correlation between BC subtype and pCR (p= 0.0138 Chi2); this was more frequent in epidermal growth factor receptor type 2 (HER2) enriched subtype patients (54%). Luminal B BC patients with a pCR had significantly lower NLR levels (t test, p= 0.0181). Conclusions: HER2-enriched tumors had a higher probability of pCR. In Luminal B tumors, NLR had a statistically significant relationship with the probability of pCR. In this subtype, NLR could be a useful biomarker to predict tumor response to NAC. Further studies including other clinical parameters for systemic inflammation such as platelet counts, intratumoral NLR or body mass index could help identify patients that would get the most benefit from NAC.
dc.fuente.origenORCID-ene24
dc.identifier.doi10.31557/apjcp.2019.20.7.2209
dc.identifier.urihttp://dx.doi.org/10.31557/apjcp.2019.20.7.2209
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/80811
dc.information.autorucEscuela de Medicina; Acevedo Claros, Francisco Nicolas; 0000-0003-3482-7746; 119540
dc.issue.numero7
dc.language.isoen
dc.nota.accesoContenido parcial
dc.pagina.final2212
dc.pagina.inicio2209
dc.revistaAsian Pacific Journal of Cancer Prevention
dc.rightsacceso restringido
dc.subjectNeutrophil to Lymphocyte Ratio
dc.subjectBreast cancer
dc.subjectLuminal subtype
dc.subjectNeoadjuvant chemotherapy
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleThe neutrophil to lymphocyte ratio predicts the response to neoadjuvant chemotherapy in luminal B breast cancer
dc.typeartículo
dc.volumen20
sipa.codpersvinculados119540
sipa.trazabilidadORCID;2024-01-08
Files
Collections
Artículos de revistas